550-CAR-T Reprogram Macrophage Tumor Microenvironment

Paper Talk · Feb 24, 2026 · 14m

This research explores a novel CAR-T cell therapy designed to treat solid tumors by targeting the tumor microenvironment rather than cancer cells directly. Scientists engineered armored CAR-T cells to deplete immunosuppressive macrophages—specifically those expressing FOLR2 or TREM2—while simultaneously delivering the potent immune stimulant IL-12. In animal models of ovarian, pancreatic, and lung cancer, this dual approach successfully eliminated pro-tumor macrophages and triggered a surge in endogenous cytotoxic T cells. This reprogramming shifted the tumor's surroundings from a suppressed…